EPO Patent for Bispecific Fusion Protein Targeting TNF-α and IL-17A

ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Published March 18th, 2026

Detected March 23rd, 2026

Summary

The European Patent Office has published patent application EP4635988A1 for a bispecific fusion protein targeting TNF-α and IL-17A, filed by Jiangsu Kanion Pharmaceutical Co., Ltd. The patent is related to therapeutic uses for conditions such as inflammation and autoimmune diseases.

View original document View source feed page

What changed

This document is a publication of a European patent application (EP4635988A1) by Jiangsu Kanion Pharmaceutical Co., Ltd. for a bispecific fusion protein designed to target both TNF-α and IL-17A. The patent covers the protein itself and its use in treating various conditions, including inflammatory, autoimmune, and joint diseases.

This is a patent filing, not a regulatory rule or enforcement action. It does not impose new compliance obligations on companies. However, it represents a development in intellectual property within the pharmaceutical sector, potentially impacting market exclusivity and future product development for competitors in the therapeutic areas covered by the patent.

Source document (simplified)

← EPO Patent Bulletin

BISPECIFIC FUSION PROTEIN TARGETING TNF-? AND IL-17A, AND USE THEREOF

Publication EP4635988A1 Kind: A1 Mar 18, 2026

Applicants

Jiangsu Kanion Pharmaceutical Co., Ltd.

Inventors

XIAO, Wei, LIU, Zhihang, SONG, Liying, YIN, Chengkai, LIU, Tianyan, YU, Dan, LI, Deshan, WANG, Zhenzhong

IPC Classifications

C07K 19/00 20060101AFI20240621BHEP C12N 15/62 20060101ALI20240621BHEP A61K 39/395 20060101ALI20240621BHEP A61K 38/17 20060101ALI20240621BHEP A61P 29/00 20060101ALI20240621BHEP A61P 37/02 20060101ALI20240621BHEP A61P 19/02 20060101ALI20240621BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →